ATE273384T1 - Tie-2 liganden, herstellungsverfahren und verwendung - Google Patents

Tie-2 liganden, herstellungsverfahren und verwendung

Info

Publication number
ATE273384T1
ATE273384T1 AT96910769T AT96910769T ATE273384T1 AT E273384 T1 ATE273384 T1 AT E273384T1 AT 96910769 T AT96910769 T AT 96910769T AT 96910769 T AT96910769 T AT 96910769T AT E273384 T1 ATE273384 T1 AT E273384T1
Authority
AT
Austria
Prior art keywords
tie
provides
human
growth
ligand
Prior art date
Application number
AT96910769T
Other languages
English (en)
Inventor
Samuel Davis
Joanne Bruno
Mitchell Goldfarb
Thomas H Aldrich
Peter C Maisonpierre
Czeslaw Radziejewski
Pamela F Jones
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/418,595 external-priority patent/US5814464A/en
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE273384T1 publication Critical patent/ATE273384T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT96910769T 1995-04-06 1996-04-05 Tie-2 liganden, herstellungsverfahren und verwendung ATE273384T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/418,595 US5814464A (en) 1994-10-07 1995-04-06 Nucleic acids encoding TIE-2 ligand-2
PCT/US1995/012935 WO1996011269A2 (en) 1994-10-07 1995-10-06 Tie-2 ligands, methods of making and uses thereof
PCT/US1996/004806 WO1996031598A1 (en) 1995-04-06 1996-04-05 Tie-2 ligands, methods of making and uses thereof

Publications (1)

Publication Number Publication Date
ATE273384T1 true ATE273384T1 (de) 2004-08-15

Family

ID=23658779

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96910769T ATE273384T1 (de) 1995-04-06 1996-04-05 Tie-2 liganden, herstellungsverfahren und verwendung

Country Status (8)

Country Link
US (1) US6627415B1 (de)
EP (1) EP0821728B1 (de)
JP (1) JP4122056B2 (de)
AT (1) ATE273384T1 (de)
AU (1) AU715621B2 (de)
CA (1) CA2216963C (de)
DE (1) DE69633121T2 (de)
WO (1) WO1996031598A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6846914B2 (en) 1996-06-19 2005-01-25 Regeneron Pharmaceuticals, Inc. Tie-2 ligand-3
FI982745A7 (fi) * 1996-06-19 1999-02-04 Regeneron Pharma TIE-2-reseptoriligandit (TIE-ligandi-3; TIE-ligandi-4) ja niiden käytt ö
US6265564B1 (en) * 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
NZ516848A (en) * 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6350450B1 (en) 1997-09-19 2002-02-26 Genentech, Inc. TIE ligand homologue antibody
US6057435A (en) 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
AU4320499A (en) * 1998-06-02 1999-12-20 Eli Lilly And Company Angiopoietin related gene sequence scarface 1
SV1999000069A (es) * 1998-06-02 2000-04-11 Lilly Co Eli Angiopoyetina relacionada con secuencia del gen 3 en la cicatrizacion de la cara ref. x-12261
WO1999067382A2 (en) * 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
WO2000012683A2 (en) * 1998-08-31 2000-03-09 New York University Stem cells bearing an fgf receptor on the cell surface
WO2000037642A1 (en) 1998-12-23 2000-06-29 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of ligands
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
ATE324444T1 (de) 1999-06-07 2006-05-15 Immunex Corp Tek-antagonisten
EP2351855A1 (de) * 2000-09-26 2011-08-03 Duke University RNA-Aptamere und Verfahren zu ihrer Identifizierung
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
AU2002335085A1 (en) 2001-10-25 2003-05-06 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
JP4242590B2 (ja) * 2002-01-11 2009-03-25 俊一 塩澤 慢性関節リウマチの疾患感受性遺伝子、及びその利用
US7427594B1 (en) * 2002-02-26 2008-09-23 The Trustees Of The University Of Pennsylvania Methods and pharmaceuticals compositions for treating coronary artery disease, ischemia,and vascular disease using angiopoietins
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
WO2004045531A2 (en) 2002-11-14 2004-06-03 Cornell Research Foundation, Inc. Protection of cardiac myocardium
US7485297B2 (en) * 2003-08-12 2009-02-03 Dyax Corp. Method of inhibition of vascular development using an antibody
US7871610B2 (en) * 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
WO2005019267A2 (en) * 2003-08-12 2005-03-03 Dyax Corp. Tie1-binding ligands
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
EP1819355A4 (de) 2004-09-28 2009-08-12 Genexel Sein Inc Verfahren zur verwendung eines chimärischen coiled-coil-moleküls
ES2371083T3 (es) 2004-12-21 2011-12-27 Medimmune Limited Anticuerpos dirigidos contra la angiopoyetina-2 y usos de los mismos.
KR101482483B1 (ko) 2006-04-07 2015-01-15 에르피오 세러퓨틱스 인코포레이티드 인간 단백질 타이로신 포스파타아제 베타(ｈｐｔｐ베타)에 결합하는 항체 및 그의 용도
US20080213253A1 (en) * 2007-01-12 2008-09-04 Dyax Corp. Combination therapy for the treatment of cancer
US8507656B2 (en) 2008-01-28 2013-08-13 Medimmune Limited Stabilized angiopoietin-2 antibodies and uses thereof
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
EP2714738B1 (de) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalente und monovalente multispezifische komplexe und ihre verwendungen
CA2850830A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
GB2516561B (en) 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
EP3116503A4 (de) 2014-03-14 2017-08-23 Aerpio Therapeutics, Inc. Hptp-beta-hemmer
KR102328327B1 (ko) 2014-09-26 2021-11-22 소마로직, 인크. 심혈관 위험 사건 예측 및 이의 용도
CN107567494A (zh) 2015-03-04 2018-01-09 迈索布拉斯特国际有限公司 间充质干细胞的细胞培养方法
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0550296A3 (en) 1991-11-28 1993-12-29 Terumo Corp Vascular endothelial cells growth factor
US5955291A (en) 1992-01-09 1999-09-21 Alitalo; Kari Antibodies recognizing tie receptor tyrosine kinase and uses thereof
AU4651893A (en) * 1992-06-26 1994-01-24 Immunex Corporation Novel tyrosine kinase
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2

Also Published As

Publication number Publication date
EP0821728A4 (de) 1998-08-19
JPH11503323A (ja) 1999-03-26
DE69633121D1 (de) 2004-09-16
EP0821728A1 (de) 1998-02-04
AU5387196A (en) 1996-10-23
EP0821728B1 (de) 2004-08-11
US6627415B1 (en) 2003-09-30
JP4122056B2 (ja) 2008-07-23
AU715621B2 (en) 2000-02-03
DE69633121T2 (de) 2005-07-28
CA2216963C (en) 2010-06-22
WO1996031598A1 (en) 1996-10-10
CA2216963A1 (en) 1996-10-10
HK1008230A1 (en) 1999-05-07

Similar Documents

Publication Publication Date Title
DE69633121D1 (de) Tie-2 liganden, herstellungsverfahren und verwendung
HUT77491A (hu) TIE-2 ligandumok, eljárás előállításukra és felhasználásuk
Akiyama et al. The product of the human c-erb B-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity
US20100040618A1 (en) Prevention of tumors with monoclonal antibodies against neu
DE68929384D1 (de) Therapeutische Zusammensetzungen die monoklonale Antikörper enthalten gegen den menschlichen Rezeptor für epidermalen Wachstumsfaktor
JP2002515511A (ja) 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
WO1994022478A1 (en) PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
BG99605A (bg) Антагонисти на растежния фактор на ендотелните клетки на кръвоносната система
FI982745A0 (fi) TIE-2-reseptoriligandit (TIE-ligandi-3; TIE-ligandi-4) ja niiden käyttö
HUP0100436A2 (hu) Emlős citokinszerű polipeptid-10
UA86768C2 (ru) ХИМЕРНОЕ МОНОКЛОНАЛЬНОЕ АНТИТЕЛО, ПОЛУЧЕННОЕ ИЗ МЫШИНОГО АНТИИДИОТИПИЧНОГО МОНОКЛОНАЛЬНОГО АНТИТЕЛА 1Е10, КОТОРОЕ РАСПОЗНАЕТ МЫШИНОЕ MAbР3
BR0312483A (pt) Anticorpos e seus usos
Barnea et al. Targeting ErbB‐1 and ErbB‐4 in irradiated head and neck cancer: Results of in vitro and in vivo studies
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
AU5873298A (en) Cathepsin k and breast cancer
CN101074262B (zh) 一种重组抗fl单克隆抗体及其制备方法和用途
Liauw Antagonists of the epidermal growth factor receptor
Dirix et al. Comparison of the in vitro cytotoxicity of the antitumour antibiotics bleomycin and mitomycin on human colorectal cancer cells and endothelial cells

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0821728

Country of ref document: EP